share_log

JP Morgan Downgrades Lyell Immunopharma to Neutral, Lowers Price Target to $5

Benzinga ·  Aug 28, 2023 04:48

JP Morgan analyst Eric Joseph downgrades Lyell Immunopharma (NASDAQ:LYEL) from Overweight to Neutral and lowers the price target from $15 to $5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment